Cancer Advance
Date: Location: Cost:
April 24, 2019 TBC
Boston, MA 02110

Starting at $1950

 

Dress Code:
Business Attire

Register

CANCER ADVANCE BOSTON - APRIL 12, 2018

2019 Agenda Coming Soon!

 

Confirmed Co-hosts and Speakers: 
Jeff AbbeyPresident & CEO, Argos Therapeutics; John BeelerVP Corporate & Business Development, Inivata; Jennifer BuellChief Communications & External Affairs Officer, Agenus; Nathan CaffoCEO & President, Presage Biosciences; Parker CassidyCCO, Mitra Biotech; Bertha ChengSenior Director, Huron Consulting Group; William Clark, CEO & President, Genocea Biosciences; Pamela ContagCEO, BioEclipse Therapeutic; Kimberly Freeman, VP Commercial Strategy & Planning, Adaptimmune; David GiljohannCEO, Exicure; Laurie GlimcherPresident & CEO, Dana Farber Cancer Institute; Arjun GoyalCo- Founder & Managing Director, Vidas Ventures; John HerrmannCSO & EVP Oncology, Elstar Therapeutics; Rachel HumphreyCMO, CytomX; Sharon KarlsbergPrincipal, ZS Associates; Liz LewisChief Counsel, Head of Patient Advocacy, Takeda; Jimmy LinCSO Oncology, Natera;  Eric OstertagCEO, Poseida Therapeutics; Robert PierceScientific Director, Immunopathology Lab, Fred Hutchinson Cancer Research Center; Johan PontinCEO, The RNA Medicines Company; Matthew PriceEVP, Phosplatin Therapeutics; James PrudentCEO, Centrose Pharma; Pawel PrzewiezlikowskiCEO, Selvita; Sridhar RamaswamyVP Translational Research & Development, Tesaro; Jon RoffmanPrincipal, ZS Associates; Benjamin RymzoManaging Director, Huron Consulting Group; Rangaprasad SarangarajanSVP & CSO, Berg; Aiman ShalabiCMO, Cancer Research Institute; Robert SilvermanPersonalized Health Care (PHC) Business Strategy & Partnering, Roche Diagnostics Division and Molecular Solution; Wenru SongPresident and Head of R&D, Kira PharmaceuticalsJames StamatisVP Business Development &  Acquisitions, AbbVie; Zhen SuCMO, EMD Serono; Lawrence TamarkinPresident & CEO, CytImmune; Elizabeth TrehuCMO, Jounce Therapeutics; Jennifer WhelerSenior Medical Director, Novartis;  Roman YelenskyEVP & CTO, Gritstone Oncology  

Time Agenda
8:00-9:00 am

Registration and Networking Breakfast

9:00-9:15 am

Welcome and Opening Remarks
Sharon Karlsberg
, Principal, ZS Associates; Pawel PrzewiezlikowskiCEOSelvita; 
Aiman ShalabiCMO, Cancer Research Institute

9:15-10:00 am

Lessons Learned from 2017
Pawel Przewiezlikowski
CEOSelvitaJon RoffmanPrincipal, ZS Associates; Robert SilvermanPersonalized Health Care (PHC) Business Strategy & PartneringRoche Diagnostics Division and Molecular Solution
Moderator: John Beeler, VP Portfolio Strategy & Life Cycle ManagementInivata

10:00-10:45 am

Staying Bold in Clinical Innovation: Oncology Drug Development 
Nathan CaffoCEO & PresidentPresage Biosciences
Rachel HumphreyCMOCytomXSridhar RamaswamyVP, Translational Research & DevelopmentTesaro
Moderator: Zhen Su, SVP & CMOEMD Serono

10:45-11:15 am

Networking Break

11:15-12:15 pm

Novel Therapeutic Approaches in Oncology
Johan PontinCEO, The RNA Medicines CompanyJames Prudent, CEOCentrose Pharma; Rangaprasad SarangarajanSVP & CSO, Berg; Roman Yelensky, EVP & CTO, Gritstone Oncology
Moderator: Chip Clark, CEO & PresidentGenocea Biosciences


12:15-12:45 pm

Fireside Chat: Patient-Centric Touchpoints: Structuring Oncology Treatment Around the Patient Journey 
Liz Lewis
, Chief Counsel, Head of Patient Advocacy, Takeda
Moderator: Pamela Contag, CEOBioEclipse Therapeutics

12:45-1:45 pm

Networking Lunch 

1:45-2:30 pm

Latest Developments in Combination Therapies
Sharon Karlsberg, Principal, ZS Associates; Matthew PriceEVPPhosplatin TherapeuticsWenru Song, President and Head of R&D, Kira Pharmaceuticals;  Elizabeth Trehu, CMO, Jounce Therapeutics
Moderator: Lawrence Tamarkin, President & CEO, CytImmune

2:30-3:15 pm

Immuno-Oncology: Challenges & Opportunities 
Jennifer BuellChief Comunications &  External Affairs OfficerAgenus; David GiljohannCEO, Exucure; Jimmy Lin, CSO OncologyNateraAiman ShalabiCMO, Cancer Research Institute
Moderator: Bertha ChengSenior Director, Huron Consulting Group

3:15-3:45 pm

Networking Break

3:45-4:30 pm

Discovery Stage and Pre-Clinical Combination Therapy
Pamela ContagCEOBioEclipse Therapeutics; Russell LaMontagnePresident & CEOBoston Immune Technologies & TherapeuticsJames StamatisVP Business Development & Acquisitions, AbbVie
Moderator: Parker CassidyCCOMitra Biotech

4:30-4:45 pm

Closing Remarks - Day One  

4:45-5:45 pm

Cocktails and Hors d'oeuvres

APRIL 13, 2018

2019 Agenda Coming Soon!

 

Confirmed Co-hosts and Speakers: 
Jeff AbbeyPresident & CEO, Argos Therapeutics; John BeelerVP Corporate & Business Development, Inivata; Jennifer BuellChief Communications & External Affairs Officer, Agenus; Nathan CaffoCEO & President, Presage Biosciences; Parker CassidyCCO, Mitra Biotech; Bertha ChengSenior Director, Huron Consulting Group; William Clark, CEO & President, Genocea Biosciences; Pamela ContagCEO, BioEclipse Therapeutic; Kimberly Freeman, VP Commercial Strategy & Planning, Adaptimmune; David GiljohannCEO, Exicure; Laurie GlimcherPresident & CEO, Dana Farber Cancer Institute; Arjun GoyalCo- Founder & Managing Director, Vidas Ventures; John HerrmannCSO & EVP Oncology, Elstar Therapeutics; Rachel HumphreyCMO, CytomX; Sharon KarlsbergPrincipal, ZS Associates; Liz LewisChief Counsel, Head of Patient Advocacy, Takeda; Jimmy LinCSO Oncology, Natera;  Eric OstertagCEO, Poseida Therapeutics; Robert PierceScientific Director, Immunopathology Lab, Fred Hutchinson Cancer Research Center; Johan PontinCEO, The RNA Medicines Company; Matthew PriceEVP, Phosplatin Therapeutics; James PrudentCEO, Centrose Pharma; Pawel PrzewiezlikowskiCEO, Selvita; Sridhar RamaswamyVP Translational Research & Development, Tesaro; Jon RoffmanPrincipal, ZS Associates; Benjamin RymzoManaging Director, Huron Consulting Group; Rangaprasad SarangarajanSVP & CSO, Berg; Aiman ShalabiCMO, Cancer Research Institute; Robert SilvermanPersonalized Health Care (PHC) Business Strategy & Partnering, Roche Diagnostics Division and Molecular Solution; Wenru SongPresident and Head of R&D, Kira PharmaceuticalsJames StamatisVP Business Development &  Acquisitions, AbbVie; Zhen SuCMO, EMD Serono; Lawrence TamarkinPresident & CEO, CytImmune; Elizabeth TrehuCMO, Jounce Therapeutics; Jennifer WhelerSenior Medical Director, Novartis;  Roman YelenskyEVP & CTO, Gritstone Oncology  

Time Agenda
8:00-9:00 am

Registration and Networking Breakfast

9:00-9:15 am

Welcome and Opening Remarks
Jeff Abbey
President & CEOArgos Therapeutics; Lawrence TamarkinPresident & CEO, CytImmune

9:15-10:00 am

Not Your Typical Drug: Advancements in CAR T-cell Therapies
Kimberly FreemanVP Commercial Strategy & Planning, Adaptimmune; Robert Pierce, Scientific Director, Immunopathology Lab, Fred Hutchinson Cancer Research Center; Eric Ostertag, CEO, Poseida Therapeutics
Moderator: 
Michael G. King, Managing Director, JMP Securities LLC

 

10:00-10:30 am

Moderated Keynote: Obstacles to Transformative Science 
Laurie Glimcher, President & CEO, Dana Farber Cancer Institute
Moderator: Benjamin RymzoManaging Director, Huron Consulting Group

10:30-11:15 am

Oncology 2018: Trends to Watch
Jeff AbbeyPresident & CEOArgos Therapeutics;  Arjun Goyal, Co-Founder & Managing Director, Vida Ventures; John HerrmannCSO & EVP OncologyElstar Therapeutics 
Moderator: Jennifer WhelerSenior Medical DirectorNovartis 

11:15-11:30 am

Closing Remarks   

Supporting Sponsors: (see all sponsors)

<